Sandbox 128: Difference between revisions
No edit summary |
No edit summary |
||
| Line 30: | Line 30: | ||
==='''B-Lactams that Inhibit PBP2a'''=== | ==='''B-Lactams that Inhibit PBP2a'''=== | ||
MRSA becomes resistant to almost all B-Lactams by acquiring an alternative TP, PBP2a, that is neither bound nor inhibited by B-Lactams. Recently, two cephlosporins- <scene name='37/372728/Ceftobiprole_alone/1'>ceftobiprole</scene> and ceftaroline- that have anti-MRSA activity have been developed. Ceftobiprole is able to inhibit PBP2a because additional chemical groups at the <scene name='37/372728/R2_group/ | MRSA becomes resistant to almost all B-Lactams by acquiring an alternative TP, PBP2a, that is neither bound nor inhibited by B-Lactams. Recently, two cephlosporins- <scene name='37/372728/Ceftobiprole_alone/1'>ceftobiprole</scene> and ceftaroline- that have anti-MRSA activity have been developed. Ceftobiprole is able to inhibit PBP2a because additional chemical groups at the <scene name='37/372728/R2_group/4'>R2</scene> position of ceftobiprole are able to interact with additional amino acid residues in PBP2a; specifically | ||
<scene name='37/372728/Tyr446_met641_interaction/1'>Tyr446 and Met641, and increase the association of ceftobiprole with PBP2a</scene>. As such, ceftobiprole is (shown as colors of the atom types [[CPK]]) is able to more efficiently react with Ser403 and therefore inhibit the activity of PBP2a. | <scene name='37/372728/Tyr446_met641_interaction/1'>Tyr446 and Met641, and increase the association of ceftobiprole with PBP2a</scene>. As such, ceftobiprole is (shown as colors of the atom types [[CPK]]) is able to more efficiently react with Ser403 and therefore inhibit the activity of PBP2a. | ||